查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014726

幽門螺旋桿菌非侵入性檢測市場：依檢測類型、技術、最終用戶和通路分類－2026-2032年全球市場預測

Helicobacter Pylori Non-invasive Testing Market by Test Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，幽門螺旋桿菌非侵入性檢測市場價值將達到 11.9 億美元，到 2026 年將成長至 12.7 億美元，到 2032 年將達到 18.8 億美元，複合年成長率為 6.70%。

主要市場統計數據
基準年 2025 11.9億美元
預計年份：2026年 12.7億美元
預測年份 2032 18.8億美元
複合年成長率 (%) 6.70%

簡要概述非侵入性幽門螺旋桿菌診斷、其臨床意義、患者治療途徑以及相關人員。

由於需要在確保診斷準確性的同時盡可能減少侵入性內視鏡檢查，非侵入性幽門螺旋桿菌檢測已成為消化不良、消化性潰瘍及相關胃部疾病診斷過程中的關鍵環節。這些檢測方法提高了患者的便利性，減輕了患者的檢查負擔，並提供了適用於門診、基層醫療機構和分散式檢查網路的替代方案。臨床醫生在選擇診斷方法時，越來越重視檢測的敏感性、特異性、出結果時間和患者依從性，這些因素正在影響整個醫療保健系統的採購和臨床路徑決策。

技術創新、檢測分散化和臨床指南的變化如何改變所有醫療機構中非侵入性幽門螺旋桿菌診斷的方式。

在技​​術進步、分散式醫療模式以及以準確性和患者便利性為優先考慮的現代臨床指南的推動下，無創幽門螺旋桿菌檢測領域正在經歷一場變革。免疫檢測平台的快速發展，以及質譜和光譜檢測法的改進，在提升分析性能的同時，也縮短了檢測結果的獲取時間。同時，數位化工作流程和遠距檢體收集的普及，使得檢測範圍不再局限於傳統的醫院檢查室，而是擴展到了基層醫療醫療機構和居家醫療場所，從而影響著臨床醫生的採納率和患者的參與度。

評估2025年美國實施的新關稅措施對供應鏈利害關係人的策略採購、定價趨勢和診斷領域的連鎖影響。

美國2025年實施的新關稅措施立即對整個診斷供應鏈產生了連鎖反應，改變了採購方式和策略採購決策。部分實驗室耗材、設備和組件的進口關稅提高，導致許多中小檢查室的總成本上升，促使採購團隊重新評估供應商組合，並優先考慮擁有本地生產設施或替代物流策略的供應商。由於檢查室努力降低價格波動風險並維持患者服務的連續性，這些變化使得供應鏈透明度和合約柔軟性變得至關重要。

透過涵蓋測試類型、技術、最終用戶和分銷管道的複雜細分分析，我們揭示了臨床採用狀況、採購行為和創新路徑。

要了解市場動態，需要採用多層次的細分方法，將偵測效能與臨床應用案例和採購邏輯連結起來。從檢測類型來看，現有產品包括血清學檢測、糞便抗原檢測和尿素呼吸檢測。血清學檢測又細分為 IgA、IgG 和 IgM 檢測，而糞便抗原調查方法則包括單株抗體和多株抗體檢測。每種檢測類型都有其獨特的臨床特徵。血清學檢測便捷，但可能反映的是既往感染而非當前性行為感染。糞便抗原檢測可直接提供性行為感染的證據，但結果可能因單株抗體和多株抗體的化學特性而異。尿素呼吸檢測如果操作正確，則具有很高的特異性，並且可以非侵入性地確認目前性行為感染。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和採用模式對商業性和臨床策略的影響。

非侵入性幽門螺旋桿菌檢測的區域趨勢受醫療基礎設施、報銷標準、臨床實踐模式和法規結構差異的影響。在美洲，檢驗的非侵入性診斷方法已在門診網路和綜合醫療保健系統中廣泛應用，並且正在積極努力將檢測流程整合到基層醫療工作流程中。在歐洲、中東和非洲，由於法規環境和報銷政策的多樣性，各國之間存在顯著差異。一些市場正在迅速採用先進技術，而另一些市場則優先考慮能夠滿足基本診斷需求的、具有成本效益的檢測方法。

對非侵入性幽門螺旋桿菌診斷生態系統中的主要企業、創新者和細分領域專家進行競爭定位和能力評估。

非侵入性幽門螺旋桿菌診斷領域的競爭格局複雜多樣，既有成熟的儀器製造商，也有專業的試劑供應商，還有致力於開發即時檢測 (POC) 和分散式解決方案的創新企業。關鍵的競爭優勢包括臨床檢驗的深度、分銷網路的廣度、服務和培訓能力，以及與實驗室資訊系統和電子健康記錄整合的能力。能夠提供可靠的性能數據、完善的上市後監控和穩定的供應鏈的公司，將優先獲得採購團隊和檢查室管理人員的青睞。

產業領導者正在採取有針對性的策略行動，以加快部署速度，確保供應彈性，並最佳化診斷商業化所需的臨床證據的創建。

診斷生態系統中的領導企業應優先進行一系列有針對性的舉措，以掌握不斷變化的市場需求並降低營運風險。首先，投資進行符合當地監管要求的嚴格臨床檢驗試驗，將有助於提升臨床醫師的信心和支付者的認可度。這些試驗不僅應展現分析性能，也應反映產品在臨床實務中的明確效用。其次，透過近岸外包、雙重採購或策略性庫存夥伴關係，實現與製造商和供應商關係的多元化，可以降低關稅相關成本衝擊和物流中斷帶來的風險。

採用穩健的調查方法，結合對臨床醫生的訪談、檢查室檢驗審查、法規環境分析和使用三角測量法的二手資訊分析，以獲得嚴謹的見解。

支持這些見解的研究透過結合定性一手研究、結構化二手研究和方法學安全措施，確保了其可靠性和有效性。一手研究包括對胃腸病學家、基層醫療醫生、實驗室管理人員和採購負責人等相關人員進行深度訪談，以了解決策因素、臨床工作流程和實施障礙。這些對話有助於解讀臨床實踐中的診斷過程，並指導最終用戶選擇需要進一步研究的技術和重點領域。

綜合考慮策略意義、臨床趨勢和市場準備情況，為非侵入性幽門螺旋桿菌檢測的相關人員提取關鍵見解。

幽門螺旋桿菌的非侵入性診斷正處於轉折點，在技術進步、醫療服務分散化和監管力度加大的推動下，臨床實踐正在重塑。檢測能力的提升、獲取途徑的拓展以及保險公司對臨床效用的日益重視，為將非侵入性檢測持續整合到診斷流程中創造了條件。能夠平衡臨床有效性、供應穩定性和與保險公司合作的相關人員，將更有能力影響檢測路徑，並確保其在各種醫療環境中得到永續應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 幽門螺旋桿菌非侵入性檢測市場：依檢測類型分類

  • 血清學檢測
    • IgA 檢測
    • IgG檢測
    • IgM 檢測
  • 糞便抗原檢測
    • 單株抗體檢測
    • 多株抗體檢測
  • 尿素呼吸檢測

第9章：幽門螺旋桿菌非侵入性檢測市場：依技術分類

  • 免疫檢測
    • ELISA
    • 快速免疫檢測
  • 紅外線光譜
  • 質譜分析
    • GC-MS
    • LC-MS

第10章：幽門螺旋桿菌非侵入性檢測市場：依最終用戶分類

  • 診所
    • 胃腸病診所
    • 初級保健診所
  • 診斷檢查室
  • 醫院
    • 二級醫療醫院
    • 三級醫療醫院

第11章 幽門螺旋桿菌非侵入性檢測市場：依分銷管道分類

  • 離線
  • 線上

第12章 幽門螺旋桿菌非侵入性檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 幽門螺旋桿菌非侵入性檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 幽門螺旋桿菌非侵入性檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國無創幽門螺旋桿菌檢測市場。

第16章：中國幽門螺旋桿菌非侵入性檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Bio-Rad Laboratories, Inc.
  • BIOHIT OYJ
  • Biomerica, Inc.
  • Boditech Med Inc.
  • CerTest Biotec SL
  • Medline Industries, Inc.
  • Meridian Bioscience Inc.
  • Metabolic Solutions, Inc.
  • Quidel Corporation
  • Sekisui Chemical Co., Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437E9896A586

The Helicobacter Pylori Non-invasive Testing Market was valued at USD 1.19 billion in 2025 and is projected to grow to USD 1.27 billion in 2026, with a CAGR of 6.70%, reaching USD 1.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.19 billion
Estimated Year [2026] USD 1.27 billion
Forecast Year [2032] USD 1.88 billion
CAGR (%) 6.70%

A concise orientation to non-invasive Helicobacter pylori diagnostics, clinical relevance, patient pathways, and the evolving decision landscape for stakeholders

Non-invasive testing for Helicobacter pylori has become a pivotal component of diagnostic pathways for dyspepsia, peptic ulcer disease, and related gastric disorders, driven by the need to minimize invasive endoscopic procedures while preserving diagnostic accuracy. These tests improve patient convenience and reduce procedural burden by offering alternatives that are compatible with outpatient workflows, primary care settings, and decentralized laboratory networks. Clinicians increasingly weigh sensitivity, specificity, turnaround time, and patient adherence when selecting a diagnostic modality, and these factors shape procurement and clinical pathway decisions across healthcare systems.

As technology and clinical guidelines evolve, the decision landscape for non-invasive diagnostics is also shifting. Payers and health systems seek evidence that links testing strategies to patient outcomes and downstream resource utilization. Consequently, manufacturers and laboratories must present clear clinical validation, operational compatibility with existing instrumentation, and pathways to integrate results into electronic health records. Together, these trends are aligning to expand the role of non-invasive testing as a first-line diagnostic tool in appropriate clinical scenarios, while preserving endoscopy for complex or refractory cases.

How technological innovation, decentralization of testing, and changing clinical guidelines are reshaping non-invasive Helicobacter pylori diagnosis across care settings

The landscape of non-invasive Helicobacter pylori testing is being transformed by a convergence of technological advances, decentralized care models, and updated clinical guidance that privileges precision and patient convenience. Rapid improvements in immunoassay platforms, coupled with advances in mass spectrometry and spectrometric approaches, are enhancing analytical performance while enabling shorter turnaround times. Simultaneously, digital workflows and remote specimen collection are expanding access beyond traditional hospital laboratories and into primary care and home-based settings, which in turn influences clinician adoption and patient engagement.

Regulatory emphasis on clinical validation and reproducibility is encouraging manufacturers to invest in robust evidence packages, and payer scrutiny is accelerating the demand for health-economic justification. As clinicians adapt to non-invasive alternatives, pathways of care are being rebalanced: patients with low-risk presentations are increasingly managed with test-and-treat strategies that rely on high-performing non-invasive assays, while endoscopy is conserved for high-risk or ambiguous cases. These systemic shifts are creating new opportunities for diagnostics providers who can demonstrate clinical rigor, ease of use, and compatibility with decentralized testing environments.

Assessing the cascading effects of new United States tariff measures enacted in 2025 on supply chains, pricing dynamics, and strategic sourcing for diagnostics stakeholders

The introduction of new tariff measures in the United States in 2025 had immediate ripple effects across the diagnostics supply chain, altering procurement behavior and strategic sourcing decisions. Increased import duties on certain laboratory consumables, instruments, and components elevated landed costs for many small and mid-sized laboratories, prompting procurement teams to re-evaluate supplier portfolios and prioritize vendors with local manufacturing footprints or alternative logistics strategies. These shifts have placed a premium on supply chain transparency and contractual flexibility as laboratories seek to mitigate price volatility and maintain continuity of patient-facing services.

In response, some manufacturers accelerated nearshoring and diversified supplier bases to reduce exposure to cross-border trade frictions. For diagnostic developers that rely on specialized reagents or instrumentation components, the tariffs intensified the focus on long-term supplier relationships and vertical integration as risk-reduction tactics. Meanwhile, payers and provider procurement committees have become more attentive to the total cost of ownership, including the operational impacts of stockouts and lead-time variability. Overall, the tariff environment has strengthened incentives to de-risk sourcing, optimize inventory strategies, and invest in regional supply resilience to protect clinical continuity and preserve access to reliable non-invasive testing.

Nuanced segmentation insight across test types, technologies, end users, and distribution channels illuminating clinical adoption, procurement behavior, and innovation pathways

Understanding market dynamics requires a layered segmentation approach that links test performance to clinical use cases and procurement logic. By test type, offerings span serology tests, stool antigen tests, and urea breath tests; serology is sub-segmented into IgA, IgG, and IgM assays, while stool antigen methodologies include monoclonal and polyclonal antibody approaches. Each test type carries distinct clinical attributes: serology can be convenient but may reflect past exposure rather than active infection, stool antigen assays offer direct evidence of active infection with variations between monoclonal and polyclonal reagent chemistry, and urea breath tests provide non-invasive confirmation of active infection with robust specificity when conducted appropriately.

From a technology perspective, the market encompasses immunoassay platforms, infrared spectrometry, and mass spectrometry, with immunoassay options further divided into ELISA and rapid immunoassay modalities, and mass spectrometry techniques represented by GC-MS and LC-MS approaches. Each technological class presents trade-offs between throughput, sensitivity, equipment footprint, and capital intensity. End users include clinics, diagnostic laboratories, and hospitals; clinics segment into gastroenterology clinics and primary care clinics, while hospitals can be classified as secondary care and tertiary care institutions. Distribution channels are evolving and include both offline and online routes, with online channels enabling direct-to-consumer kit distribution and rapid supply replenishment for institutional buyers. Integrating these segmentation lenses clarifies where clinical demand intersects with procurement criteria and where innovation can yield differentiated clinical and operational value.

Regional dynamics and differentiated adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform commercial and clinical strategies

Regional dynamics in non-invasive Helicobacter pylori testing are shaped by differences in healthcare infrastructure, reimbursement norms, clinical practice patterns, and regulatory frameworks. In the Americas, there is strong uptake of validated non-invasive diagnostics within outpatient networks and integrated health systems, accompanied by active efforts to align testing pathways with primary care workflows. In Europe, Middle East & Africa, heterogeneous regulatory environments and varied reimbursement policies lead to pronounced country-level differences, where some markets adopt advanced technologies rapidly while others prioritize cost-effective assays that meet essential diagnostic needs.

Across the Asia-Pacific region, rising awareness of gastric disease epidemiology, expanding diagnostic laboratory capacity, and an emphasis on point-of-care accessibility are accelerating adoption of non-invasive testing options. These regional distinctions inform go-to-market strategies: manufacturers and distributors must tailor clinical evidence packages, pricing models, and service capabilities to local reimbursement realities and clinician preferences. Consequently, global players often pursue differentiated launch approaches, partnering with regional laboratories or in-country distributors to ensure regulatory alignment and to adapt product positioning to the specific needs of each market cluster.

Competitive positioning and capability assessment of leading players, innovators, and niche specialists in non-invasive Helicobacter pylori diagnostics ecosystems

Competitive dynamics in the non-invasive Helicobacter pylori diagnostics space are defined by a mix of established instrument manufacturers, specialized reagent suppliers, and agile innovators developing point-of-care or decentralizable solutions. Key competitive levers include the depth of clinical validation, the breadth of distribution networks, service and training capabilities, and the ability to integrate with laboratory information systems and electronic health records. Companies that can demonstrate robust performance data, strong post-market surveillance, and reliable supply operations gain preferential consideration from procurement teams and laboratory directors.

Innovation is also reshaping competitive positioning: firms that invest in multiplexing capabilities, improvements in assay sensitivity and specificity, and streamlined sample collection kits are increasingly attractive to clinics and diagnostic laboratories seeking to simplify workflows. Strategic partnerships between instrument makers and reagent vendors, as well as alliances with contract research organizations for clinical validation, are common strategies to accelerate market penetration. Moreover, organizations that provide comprehensive customer support, including clinical education and implementation services, often secure longer-term institutional relationships that extend beyond single-purchase transactions.

Targeted strategic actions for industry leaders to accelerate adoption, secure supply resilience, and optimize clinical evidence-generation for diagnostics commercialization

Leaders in the diagnostics ecosystem should prioritize a set of targeted actions to capitalize on shifting demand and to mitigate operational risks. First, investing in rigorous clinical validation studies that align with local regulatory expectations will accelerate clinician trust and payer acceptance; these studies should demonstrate not only analytical performance but also clear clinical utility within care pathways. Second, diversifying manufacturing and supplier relationships-whether through nearshoring, dual sourcing, or strategic inventory partnerships-will reduce exposure to tariff-induced cost shocks and logistical disruptions.

Third, strengthening digital and direct-to-consumer channels can expand patient access while enabling efficient specimen tracking and result delivery. Fourth, engaging early with payers and health technology assessment bodies to clarify reimbursement criteria and to present real-world evidence will support predictable adoption. Finally, establishing collaborative programs with laboratories and clinical networks for ongoing post-market surveillance and iterative product improvement will sustain competitive differentiation. Taken together, these actions create a resilient commercial model that balances innovation with operational reliability and payer-aware evidence generation.

Robust research methodology combining clinician interviews, laboratory validation review, regulatory mapping, and triangulated secondary intelligence for rigorous findings

The research underpinning these insights combines qualitative primary engagement, structured secondary review, and methodological safeguards to ensure reliability and relevance. Primary research included in-depth interviews with clinical stakeholders such as gastroenterologists, primary care physicians, laboratory directors, and procurement professionals to capture decision drivers, clinical workflows, and adoption barriers. These conversations informed the interpretation of real-world diagnostic pathways and guided the selection of technology and end-user focus areas for deeper investigation.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, technical white papers, and manufacturer technical specifications to corroborate clinical and technical assertions. Regulatory mapping identified local approval pathways and post-market requirements, while a review of recent patent filings and academic publications highlighted innovation trajectories. Data synthesis relied on triangulation across sources to reconcile discrepancies and to build a coherent narrative. Quality assurance steps included expert validation of key findings and sensitivity checks on thematic conclusions to ensure that recommendations remain robust across diverse clinical and operational contexts.

Synthesis of strategic implications, clinical momentum, and market readiness that distills key takeaways for stakeholders in non-invasive Helicobacter pylori testing

Non-invasive diagnostics for Helicobacter pylori are at an inflection point where technological improvements, decentralized care delivery, and heightened regulatory scrutiny converge to reshape clinical practice. The combined momentum of improved assay performance, expanded access pathways, and payer attention to clinical utility creates conditions for more consistent incorporation of non-invasive tests into diagnostic algorithms. Stakeholders that align clinical validation, supply resilience, and payer engagement will be best positioned to influence care pathways and to secure durable adoption across diverse healthcare settings.

Looking ahead, continued emphasis on real-world evidence generation and operational integration will determine which technologies achieve long-term clinical traction. Manufacturers and laboratories that proactively address clinician needs, streamline workflows, and demonstrate the patient-centered benefits of non-invasive testing will find the most receptive audiences. Ultimately, the most successful strategies will balance scientific rigor with practical considerations of cost, access, and ease of implementation to support better outcomes for patients and more predictable operational performance for healthcare providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Non-invasive Testing Market, by Test Type

  • 8.1. Serology Test
    • 8.1.1. IGa Test
    • 8.1.2. IGg Test
    • 8.1.3. IGm Test
  • 8.2. Stool Antigen Test
    • 8.2.1. Monoclonal Antibody Test
    • 8.2.2. Polyclonal Antibody Test
  • 8.3. Urea Breath Test

9. Helicobacter Pylori Non-invasive Testing Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Elisa
    • 9.1.2. Rapid Immunoassay
  • 9.2. Infrared Spectrometry
  • 9.3. Mass Spectrometry
    • 9.3.1. Gc Ms
    • 9.3.2. Lc Ms

10. Helicobacter Pylori Non-invasive Testing Market, by End User

  • 10.1. Clinics
    • 10.1.1. Gastroenterology Clinic
    • 10.1.2. Primary Care Clinic
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
    • 10.3.1. Secondary Care Hospital
    • 10.3.2. Tertiary Care Hospital

11. Helicobacter Pylori Non-invasive Testing Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Helicobacter Pylori Non-invasive Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Helicobacter Pylori Non-invasive Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Helicobacter Pylori Non-invasive Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Helicobacter Pylori Non-invasive Testing Market

16. China Helicobacter Pylori Non-invasive Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. ACON Laboratories, Inc.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. BIOHIT OYJ
  • 17.9. Biomerica, Inc.
  • 17.10. Boditech Med Inc.
  • 17.11. CerTest Biotec S.L.
  • 17.12. Medline Industries, Inc.
  • 17.13. Meridian Bioscience Inc.
  • 17.14. Metabolic Solutions, Inc.
  • 17.15. Quidel Corporation
  • 17.16. Sekisui Chemical Co., Ltd.
  • 17.17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 189. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 221. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 222. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 232. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 233. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)